Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab with and without nivolumab in advanced solid tumors and melanoma
NL-OMON59713Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of relatlimab and nivolumab in Nonhematologic neoplasms, melanoma, non-small cell lung cancer (NSCLC) and 8 more (7 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Proportion of subjects with adverse events, Proportion of subjects with serious adverse events and 9 more. Started Dec 2016; status: completed.
02
Drugs
relatlimabnivolumab
03
Conditions
Nonhematologic neoplasmsmelanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON59713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59713.